ECB-ART-49847
J Oncol Pharm Pract
2020 Dec 01;268:2031-2033. doi: 10.1177/1078155220919172.
Show Gene links
Show Anatomy links
Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient.
???displayArticle.abstract???
INTRODUCTION: Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. CASE REPORT: In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC).Management and outcome: She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event. DISCUSSION: Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.
???displayArticle.pubmedLink??? 32340536
???displayArticle.link??? J Oncol Pharm Pract